1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Castle Biosciences, Inc.

Castle Biosciences, Inc.

CSTL
Castle Biosciences, Inc.US flagNASDAQ Global Market
23.90
USD
-0.26
- -
724.73MMarket Cap

Total Valuation

Castle Biosciences, Inc. carries a market capitalization of 724.73M, placing it among publicly traded companies globally. Its enterprise value stands at 494.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap724.73M
Enterprise Value494.41M

Share Statistics

Castle Biosciences, Inc. currently has 30.30M shares outstanding.

Shares Outstanding30.30M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 2.12, and the price-to-book ratio stands at -3.01.

PE RatioN/A
PS Ratio2.12
PB Ratio-3.01
P/TBV Ratio1.98
P/FCF Ratio7.86
P/OCF Ratio14.91

Enterprise Valuation

On an enterprise value basis, Castle Biosciences, Inc. trades at an EV/EBITDA multiple of 70.67 and an EV/FCF ratio of 5.37.

EV / Sales1.45
EV / EBITDA70.67
EV / EBITN/A
EV / FCF5.37

Financial Position

Castle Biosciences, Inc. maintains a current ratio of 6.75, meaning it holds 6.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.96, indicating elevated leverage, while an interest coverage ratio of -90.41 demonstrates limited ability to service its debt obligations.

Current Ratio6.75
Quick Ratio6.23
Debt / Equity7.96
Debt / EBITDA-2.00
Interest Coverage-90.41

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-2.45
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover8.69

Taxes

Income Tax-4.82M
Effective Tax RateN/A

Stock Price Statistics

Castle Biosciences, Inc.'s stock has gained approximately 42.91268% over the past 52 weeks. The 50-day moving average sits at 21.57, while the 200-day moving average is 28.76.

Beta (5Y)N/A
52-Week Price Change42.91268%
50-Day Moving Average21.57
200-Day Moving Average28.76
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Castle Biosciences, Inc. generated 339.92M in revenue and converted that into -12.83M in net income, yielding earnings per share of -0.44. EBITDA reached -18.35M, while operating income came in at -33.29M.

Revenue339.92M
Gross Profit264.74M
Operating Income-33.29M
Pretax Income-17.66M
Net Income-12.83M
EBITDA-18.35M
EBIT-33.29M
Earnings Per Share (EPS)-0.44

Balance Sheet

Castle Biosciences, Inc. holds 261.69M in cash and equivalents against 36.72M in total debt, resulting in a net debt position of -53.70M. Total book value stands at -238.78M, with working capital of 280.14M providing operational flexibility.

Cash & Cash Equivalents261.69M
Total Debt36.72M
Net Debt-53.70M
Equity (Book Value)-238.78M
Book Value Per Share-8.15
Working Capital280.14M

Cash Flow

Castle Biosciences, Inc. produced 48.25M in operating cash flow over the past twelve months. After subtracting -43.74M in capital expenditures, free cash flow totaled 4.52M - equivalent to 0.15 per share.

Operating Cash Flow48.25M
Capital Expenditures-43.74M
Free Cash Flow4.52M
FCF Per Share0.15

Margins

Castle Biosciences, Inc. operates with a gross margin of 77.88, reflecting its pricing power and cost economics. The operating margin of -9.79 and net profit margin of -3.78 provide insight into operational efficiency.

Gross Margin77.88
Operating Margin-9.79
Pretax Margin-5.19
Profit Margin-3.78
EBITDA Margin-5.40

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield1.45
FCF Yield12.72

Scores

Castle Biosciences, Inc. posts an Altman Z-Score of 5.51, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.51